- Home
- PVLA
as 04-18-2025 1:42pm EST
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. It is developing a broad pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Palvella's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 308.2M | IPO Year: | N/A |
| Target Price: | $44.43 | AVG Volume (30 days): | 97.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.20 - $29.27 | Next Earning Date: | 05-15-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Palvella Therapeutics Inc. Common Stock News
PVLA Breaking Stock News: Dive into PVLA Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University’s Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology
GlobeNewswire
15 days ago
Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference
GlobeNewswire
17 days ago
Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology
GuruFocus.com
18 days ago
Palvella Therapeutics Inc (PVLA) Q4 2024 Earnings Call Highlights: Navigating Financial ...
GlobeNewswire
19 days ago
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
a month ago
Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025
Simply Wall St.
a month ago
Individual investors who hold 41% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) gained 12%, insiders profited as well
Insider Monkey
2 months ago
Why Palvella Therapeutics, Inc. (PVLA) is Skyrocketing So Far in 2025
Compare PVLA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PVLA Palvella Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.